{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:23:20Z","timestamp":1791440600321,"version":"4.3.3"},"reference-count":27,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dolutegravir (DTG)-based antiretroviral treatment is now the recommended regimen because of its high efficacy and fewer adverse effects. Nonetheless, hyperglycemia as adverse effect of DTG was reported in few clinical observations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A case-control study was carried out among DTG-based antiretroviral therapy (ART) users during the study period. EPI Info version 4.8 and SPSS version 26 were used for data entry and analysis, respectively. Binary logistic regression model was used to determine association between risk factors and outcome measures. The associated factors of hyperglycemia were identified using the odds ratio. A\n                      <jats:italic>P-<\/jats:italic>\n                      value &lt;.05 was used to test significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study contained 42 cases (DTG-based ART users who developed hyperglycemia) and 84 controls (DTG-based ART users who didn\u2019t develop hyperglycemia). On bivariable analysis, lower base-line CD4 count, greater body mass index, and lower grade school attendees were significant at\n                      <jats:italic>P<\/jats:italic>\n                      -value &lt;.25. On multivariable analysis, overweight\/obesity (body mass index \u226525) plausibly approached statistical significance but did not reach conventional threshold (\n                      <jats:italic>P<\/jats:italic>\n                      -value&lt;.05) as risk factor for hyperglycemia among DTG-based ART users.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overweight\/obesity-driven hyperglycemia secondary to insulin resistance might be the explanation for hyperglycemia among DTG-based ART users. Further studies with larger sample sizes and prospective designs are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23259582251375873","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T16:32:03Z","timestamp":1757435523000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Determinants of Hyperglycemia in Adult People Living With HIV Taking Dolutegravir- Based Antiretroviral Therapy at University of Gondar Hospital, North West Ethiopia, 2022: A Case-Control Study"],"prefix":"10.1177","volume":"24","author":[{"given":"Addisu","family":"Liknaw","sequence":"first","affiliation":[{"name":"Woldia Comprehensive Specialized hospital, Woldia, North Wollo, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3966-4969","authenticated-orcid":false,"given":"Abilo","family":"Tadesse","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Workagegnehu","family":"Hailu","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsebaot","family":"Tesfaye","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melaku","family":"Tadesse","sequence":"additional","affiliation":[{"name":"Department of Internal medicine, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1391"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30093-6"},{"key":"e_1_3_3_4_2","unstructured":"WHO. Update of Recommendations on First- and Second-Line Antiretroviral Regimens; WHO\/CDS\/HIV\/19.15; World Health Organization: Geneva Switzerland 2019."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S58706"},{"key":"e_1_3_3_6_2","unstructured":"Federal Ministry of Health (FMOH). National Consolidated Guidelines for Comprehensive HIV Prevention Care and Treatment. Addis Ababa Ethiopia 2018."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30042-4"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SUN-187"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx365"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz407"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871526518666180723152715"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1916"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18083926"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-014-0219-7"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007413"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2023.1133556"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1403"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/09564624221129410"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","unstructured":"Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15\u2013S33.","DOI":"10.2337\/dc21-S002"},{"issue":"1","key":"e_1_3_3_20_2","article-title":"SUN-187 dolutegravir causing diabetes","volume":"3","author":"Kamal P","year":"2019","unstructured":"Kamal P, Sharma S. SUN-187 dolutegravir causing diabetes. J Endocr Soci. 2019;3(Supplement_1):SUN-187.","journal-title":"J Endocr Soci"},{"key":"e_1_3_3_21_2","volume-title":"345. Acute Onset Diabetic Ketoacidosis\/Hyperosmolar Hyperglycemic State in Patients Taking Integrase Strand Transfer Inhibitors. Open Forum Infectious Diseases","author":"Ntem-Mensah AD","year":"2019","unstructured":"Ntem-Mensah AD, Millman N, Jakharia N, Theppote A, Toeque M-G, Riedel DJ, eds. 345. Acute Onset Diabetic Ketoacidosis\/Hyperosmolar Hyperglycemic State in Patients Taking Integrase Strand Transfer Inhibitors. Open Forum Infectious Diseases. Oxford University Press US; 2019."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S323233"},{"key":"e_1_3_3_23_2","first-page":"01","article-title":"Experience of dolutegravir-based antiretroviral treatment and risk of diabetes mellitus","volume":"10","author":"Hirigo AT","year":"2022","unstructured":"Hirigo AT, Gutema S, Eifa A, Ketema W. Experience of dolutegravir-based antiretroviral treatment and risk of diabetes mellitus. Sage Open Med Case Rep. 2022;10:01\u201304.","journal-title":"Sage Open Med Case Rep"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/venereology3020008"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.13140\/RG.2.2.35709.54247-63."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2023.100235"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa330"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-023-00510-6"}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582251375873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23259582251375873","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582251375873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:50:44Z","timestamp":1777503044000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23259582251375873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"alternative-id":["10.1177\/23259582251375873"],"URL":"https:\/\/doi.org\/10.1177\/23259582251375873","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"23259582251375873"}}